AI Article Synopsis

  • AIT (Allergen Immunotherapy) lacks clear guidelines for treating atopic dermatitis (AD), but this study aims to evaluate its effects on patients allergic to house dust mites (HDM).
  • A placebo-controlled trial involved 61 patients with moderate-to-severe AD, who received either HDM allergen extract or a placebo for 12 months, measuring improvement through various indicators.
  • Results showed that 15 of the 24 patients receiving AIT experienced significant improvement, while no improvements were observed in the placebo group; effectiveness was notably higher for patients sensitized to specific HDM molecules.

Article Abstract

Introduction: Allergen immunotherapy (AIT) has no clear recommendation for atopic dermatitis (AD).

Aim: To evaluate the effect of AIT on house dust mites (HDM) in AD patients sensitised to HDM with different baseline molecular profiles of antigens.

Material And Methods: In this placebo-controlled study, 61 patients with moderate-to-severe AD allergy symptoms and HDM allergy were included. They received a 12 months' AIT with the use of HDM allergen extract or placebo. The authors adopted their AD improvement criterion after 1 year of AIT as a reduction of all examined indicators by at least 50% from the baseline for %BSA, TMS, and EASI scores. Additionally, the influence of individual HDM molecules on the final AIT effect was analysed.

Results: Finally, from the 24 desensitised patients, 15 achieved a positive expected effect after 12 months of HDM AIT. None of the patients who received a placebo had an improvement in AD of at least 50% after 1 year of follow-up. Patients with polysensitisation less frequently achieved the expected HDM AIT effect than patients monosensitised to mites ( < 0.05). The presence of sensitisation to rDer p 1 (odds ratio = 4.35, 95% CI: 4.01-4.56) and/or rDer p 2 (OR = 2.16, 95% CI: 1.98-2.33) and/or rDer f 2 (OR = 1.41, 95% CI: 1.55-1.78) molecules significantly increased the efficacy of AIT. HDM AIT could be helpful for patients with moderate-to-severe AD and sensitised to HDM as an add-on therapy. Various HDM molecules may affect the effectiveness of the expected AIT effect. The presence of sensitisation to rDer p 1 (OR = 4.35, 95% CI: 4.01-4.56) and/or rDer p 2 (OR = 2.16, 95% CI: 1.98-2.33) and/or rDer f 2 (OR = 1.41, 95% CI: 1.55-1.78) molecules significantly increased the efficacy of AIT.

Conclusions: HDM AIT could be helpful for patients with moderate-to-severe AD and sensitised to HDM as an add-on therapy. Various HDM molecules may affect the effectiveness of the expected AIT.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485758PMC
http://dx.doi.org/10.5114/ada.2023.129456DOI Listing

Publication Analysis

Top Keywords

hdm ait
16
and/or rder
16
hdm
13
ait
12
sensitised hdm
12
patients moderate-to-severe
12
hdm molecules
12
allergen immunotherapy
8
atopic dermatitis
8
house dust
8

Similar Publications

[Clinical efficacy of sublingual immunotherapy for allergic rhinitis].

Nihon Yakurigaku Zasshi

January 2025

Department of Otolaryngology, Head and Neck Surgery, Graduate School of Medicine, Chiba University.

The prevalence of allergic rhinitis (AR) reached 49.2% in 2019. In particular, the prevalence of Japanese cedar (JC) pollinosis is 38.

View Article and Find Full Text PDF

In the overall Japanese population, the prevalence of perennial allergic rhinitis (AR) increased from 18.7% to 24.5% from 1998 to 2019.

View Article and Find Full Text PDF

Background: Allergen immunotherapy (AIT) aims at modulating the immune response by administration of allergen preparations at regular intervals over several years (1). For subcutaneous AIT (SCIT), the treatment is initiated with a dose escalation phase followed by a maintenance dose administration. Over the last decade, there has been a trend towards shortening dose escalation regimens to increase patient adherence.

View Article and Find Full Text PDF

Effect and mechanism of allergen-specific immunotherapy on small airway dysfunction in children with asthma.

Pediatr Pulmonol

October 2024

Department of Respiratory Medicine, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

Background: The purpose of this study was to investigate the effectiveness of allergen-specific immunotherapy (AIT) on small airway dysfunction (SAD) and the underlying mechanism with a special focus on basophils.

Methods: Sixty-five children with mild to moderate asthma who were under regular inhaled corticosteroid (ICS) treatment for more than 1 year but whose FEF remained below 65% of the predicted value and had positive results for serum Der p or Der f were enrolled. Children with asthma underwent house dust mite (HDM) subcutaneous immunotherapy (SCIT) treatment for 1 year.

View Article and Find Full Text PDF

Cost-effectiveness of allergen immunotherapy.

Curr Opin Allergy Clin Immunol

December 2024

Servicio de Alergia, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS) Madrid, Spain. University of Alcalá (UAH).

Article Synopsis
  • Allergic rhinitis is a common health problem, affecting many people and getting worse because of climate change and pollution.
  • Allergen immunotherapy (AIT) is a special treatment that can help people with allergies, and it's shown to be effective and cost-effective compared to standard treatments.
  • Recent studies found that AIT treatments like subcutaneous and sublingual immunotherapy are not just effective but also save money in the long run, especially when combined with other treatments for allergies and asthma.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!